Managed Care Review of Unmet Medical Needs, New Treatments, and Health Economics Associated with Schizophrenia - Payer Forum

https://www.pharmacytimes.org/on-demand/a-managed-care-review-of-unmet-medical-needs-new-treatments-and-health-economics-associated-with-schizophrenia

Related Videos

Related Content

Advertisement

July 19th 2025

As CMS Embarks on “Rural Transformation,” a New Jersey Health System Weighs In

Mary Caffrey

CMS Administrator Mehmet Oz, MD, MBA, visited AtlantiCare leaders in Atlantic City, New Jersey, to discuss the need for legislative and regulatory reform, as well as the $50 billion Rural Transformation Program.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

July 18th 2025

Higher BMI Linked to Lower Mortality Rate, Fewer Complications in Non-CF Bronchiectasis

Brooke McCormick

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while being underweight increases health complications.

July 8th 2025

Managed Care Cast News Roundup: July 8, 2025

Giuliana Grossi

Medical societies challenge HHS Secretary Robert F. Kennedy Jr's COVID-19 vaccine rollbacks, and more news updates from the week.

July 18th 2025

Semaglutide, Tirzepatide Cut Dementia, Stroke Risk in Type 2 Diabetes

Pearl Steinzor

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

July 18th 2025

FDA Delivers a CRL to Glofitamab for Relapsed/Refractory DLBCL

Maggie L. Shaw

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Related Content

Advertisement

July 19th 2025

As CMS Embarks on “Rural Transformation,” a New Jersey Health System Weighs In

Mary Caffrey

CMS Administrator Mehmet Oz, MD, MBA, visited AtlantiCare leaders in Atlantic City, New Jersey, to discuss the need for legislative and regulatory reform, as well as the $50 billion Rural Transformation Program.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

July 18th 2025

Higher BMI Linked to Lower Mortality Rate, Fewer Complications in Non-CF Bronchiectasis

Brooke McCormick

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while being underweight increases health complications.

July 8th 2025

Managed Care Cast News Roundup: July 8, 2025

Giuliana Grossi

Medical societies challenge HHS Secretary Robert F. Kennedy Jr's COVID-19 vaccine rollbacks, and more news updates from the week.

July 18th 2025

Semaglutide, Tirzepatide Cut Dementia, Stroke Risk in Type 2 Diabetes

Pearl Steinzor

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

July 18th 2025

FDA Delivers a CRL to Glofitamab for Relapsed/Refractory DLBCL

Maggie L. Shaw

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).